VEGFR1/2/3

Notes

original target text: VEGFR1/2/3 inhibitor

VEGFR1, VEGFR2, and VEGFR3 are receptor tyrosine kinases expressed mainly on the surface of vascular and lymphatic endothelial cells. They are activated by members of the vascular endothelial growth factor (VEGF) family, and their signaling drives angiogenesis—the formation of new blood vessels—and lymphangiogenesis, the formation of lymphatic vessels. In cancer, tumors co-opt this pathway to build the blood supply needed for growth and spread, making VEGFR blockade a long-standing strategy to starve tumors of nutrients and oxygen. The same pathway also underlies pathological vessel growth in certain eye diseases, where abnormal, leaky vessels form in the retina or choroid and threaten vision. A small-molecule inhibitor that blocks all three receptors, rather than just one, interrupts multiple parallel routes by which VEGF ligands can trigger vessel growth, since VEGFR1 and VEGFR3 can partly compensate when VEGFR2 alone is inhibited. This broad blockade is intended to produce a more complete anti-angiogenic effect. Because VEGF signaling is also required for normal vascular maintenance, inhibiting it broadly carries mechanistic trade-offs relevant across the therapeutic contexts where this target class is used.